Generated by AI
Summary of Nov 18's posts. Generated by AI.
Summary of Jun 2's posts. Generated by AI.
Summary of Feb 5's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about CING also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing drug delivery-based therapies for attention deficit/hyperactivity disorder (ADHD) and anxiety. Its Precision Timed Release platform is designed to support once-daily tablet formulations and improve how multi-dose medicines are delivered in routine treatment settings. The company’s current pipeline includes CTx-1301, a dexmethylphenidate-based candidate for ADHD in children, adolescents, and adults, and CTx-2103, a buspirone-based formulation for anxiety. Cingulate also works on additional stimulant candidates within the same platform to address common psychiatric and behavioral conditions. Based in Kansas City, Kansas, Cingulate serves the biopharmaceutical market through specialized product development centered on chronic conditions that require consistent daily dosing and targeted drug release.
Website1901 West 47th Place
Kansas City, KS, 66205
United States
The latest articles about CING.
Detailed price information for Cingulate Inc (CING-Q) from The Globe and Mail including charting and trades.
Tipranks Press Release.